Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial

Dual antiplatelet therapy, with combination aspirin and clopidogrel, is now standard of care in the secondary prevention of minor stroke and transient ischemic attack1 –3 as well as stroke due to intracranial atherosclerotic disease.4 However, in the Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events (CHANCE)2 and Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT)3 randomized clinical trials, determination of the etiology of ischemic stroke was not required to initiate secondary prevention.

Source: Journal of Stroke and Cerebrovascular Diseases - August 13, 2020 Category: Neurology Authors: Zachary Bulwa, Faddi G. Saleh Velez, James R. Brorson, Camila B. Pinto Source Type: research